Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

389.98
USD
+10.48
(+2.76%)
38.15EPS
9.55P/E
9.77BMarket Cap
Feb 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
74.94
75.66
69.5
70.56
73.16
77.07
77.8
85.89
98.4
94.5
91.86
91.37
95.17
96.94
Basic EPS, GAAP
2.73
3.09
3.76
0.89
4.14
12.31
59.19
128.7
143.24
-122.33
-21.92
-65.65
28
38.24
Free Cash Flow per Basic Share
5.92
8.97
6.36
7.37
3.4
9.61
12.1
16.07
18.04
2.7
7.5
9.48
13.8
12.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
76.33
75.5
85.2
87.59
98.81
135.51
193.16
332.52
459.23
326.32
307.87
235.56
277.38
283.99
Tangible Book Value per Share
48.96
49.43
60.92
65.9
75.88
123.61
179.42
315.98
439.05
301.26
282.01
210.31
249.32
258.68
Basic Weighted Avg Shares
28
29
29
29
30
30
30
30
30
30
29
28
27
27
Sales/Revenue/Turnover
2,133
2,175
2,019
2,068
2,160
2,289
2,312
2,546
2,923
2,802
2,671
2,567
2,583
2,593
Operating Margin (%)
7.95
6.9
8.26
5.71
6.05
8.26
9.93
16.55
17.12
16.95
12.65
10.48
8.46
6.2
Depreciation Expense
147
150
132
143
149
138
134
139
138
137
146
152
165
166
Net Income, GAAP
78
89
109
26
122
366
1,759
3,814
4,254
-3,627
-637
-1,844
760
1,023
Effective Tax Rate (%)
30.76
32.47
25.1
37.44
- -
28.68
22.22
22.44
21.93
- -
- -
- -
23.67
22.52
Profit Margin (%)
3.65
4.08
5.41
1.26
5.66
15.97
76.08
149.83
145.57
-129.45
-23.86
-71.86
29.42
39.45
Working Capital
1,270
1,270
1,336
1,373
1,474
1,573
1,275
1,508
1,310
2,589
2,526
2,563
2,389
2,110
LT Debt
436
436
434
434
435
439
190
187
186
1,351
1,365
1,332
1,349
931
Total Equity
2,187
2,185
2,491
2,579
2,930
4,020
5,755
9,880
13,685
9,615
8,741
6,569
7,454
7,603
Return on Invested Capital (%)
4.36
3.86
4.49
1.17
- -
-1.87
3.27
3.95
3.24
- -
- -
- -
0.43
-0.56
Return on Capital (%)
4.47
3.96
4.53
1.37
- -
9.78
32.71
46.41
35.44
- -
- -
- -
9.5
12.41
Return on Common Equity (%)
3.7
4.06
4.67
1.03
4.44
10.52
35.98
48.79
36.11
-31.14
-6.94
-24.09
10.84
14.27

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
437
434
433
LT Borrowings
803
803
803
LT Finance Leases
139
133
128
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
7,432
7,893
9,774

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,942
3,021
3,079
Cash, Cash Equivalents & STI
1,565
1,619
1,664
Accounts Receivable, Net
426
442
423
Inventories
771
781
784
Total Current Liabilities
917
961
969
Payables & Accruals
326
368
382
ST Debt
437
434
433
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.75%
-2.34%
13.46%
Free Cash Flow
36.88%
32.51%
40.72%
Net Income, GAAP
78.3%
-41.6%
-141.2%
Sales/Revenue/Turnover
2.67%
0.55%
0.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
611
639
650
667
2,567
2025
585
652
653
693
2,583
2026
592
651
656
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.52
-76.6
23.47
-25.68
-65.65
2025
2.3
11.72
-12.76
26.81
28
2026
-19.64
13.95
17.2
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Norman D. Schwartz
Full Time Employees
7,450
Sector
Health technology
Industry
Medical specialties
Address
1000 Alfred Nobel Drive Hercules CA United States 94547
IPO Date
Mar 17, 1980
Business
Bio-Rad Laboratories, Inc. is a global leader in the development and manufacture of life science research and clinical diagnostics products. Founded in 1952 and headquartered in Hercules, California, the company operates internationally across the United States, Europe, Asia, Canada, and Latin America. Bio-Rad's core products span life science research instruments and consumables, including chromatography resins and media, flow cytometry antibodies, Droplet Digital PCR (ddPCR) platforms and reagents, as well as advanced digital PCR solutions designed for genomic research and applied sciences. In clinical diagnostics, Bio-Rad offers systems and assays for autoimmune testing, infectious disease detection, diabetes monitoring, blood typing and screening, cardiac assessment controls, molecular quality controls, veterinary diagnostics, and water quality testing. The company serves a broad range of customers from research institutions to clinical, hospital, and veterinary laboratories. Recent major changes include the acquisition of Stilla Technologies in the second quarter of 2025, which enhances Bio-Rad's digital PCR portfolio by integrating Stilla’s QX700 series instruments with Bio-Rad's existing QX Continuum system, thereby accelerating innovation in molecular diagnostics and precision medicine. In 2024, Bio-Rad also completed the acquisition of Saber Bio, a company focused on droplet technology for antibody discovery, aligning with its expansion in cell biology products. Additionally, Bio-Rad has launched new products such as the StarBright dyes for flow cytometry to improve multiplexing capabilities and kits for precise mutation detection in oncology applications leveraging its ddPCR technology. These developments support the company’s strategic focus on enhancing automation, throughput, and the sensitivity of its diagnostics platforms, further positioning it as a key player in advancing life science research and clinical diagnostic solutions. Bio-Rad continues to invest in transformative technologies such as Droplet Digital PCR for non-invasive cancer screening and gene therapy production, supported by ongoing product development and expansion of its assay portfolio. The company’s broad product offering includes instruments, software, reagents, and specialized consumables designed to support applications in cell biology, gene expression, protein purification, drug discovery, infectious diseases, and transfusion medicine. With a commitment to innovation and global healthcare advancement, Bio-Rad maintains a strong presence in both the life sciences and clinical diagnostics markets, driving growth through strategic acquisitions, product launches, and enhanced service offerings.

Company News

  • Insider Selling: Bio-Rad Laboratories (NYSE:BIO) EVP Sells $539,882.00 in Stock

  • Bio-Rad Laboratories (NYSE:BIO) Stock: Insider Courtney Enloe Sells 902 Shares

  • Bio-Rad Laboratories (NYSE:BIO) Stock: Insider Jonathan Divincenzo Sells 919 Shares

  • Bio-Rad Laboratories (NYSE:BIO) Stock: Insider James Barry Sells 1,400 Shares

  • Bio-Rad Laboratories, Inc. $BIO Stock Sold by Fisher Asset Management LLC

  • BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ET

  • BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

  • BIO-key Enters Gaming / Hospitality Market with Contract from Major U.S. Casino Resort

  • Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript

  • Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.

  • Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention

  • Medicus Pharma to Present at BIO-Europe 2026

  • What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call

  • Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript

  • Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates

  • Bio-Rad Reports Third-Quarter 2026 Financial Results

  • BIO-TECHNE DECLARES DIVIDEND

  • Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal

  • Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference

  • BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government's National Security Ecosystem